$NICE

NICE Ltd.

AlphAI earnings readQ2 FY2026 · AUG 5NiCE Exceeds Revenue Guidance Range, Reporting 8% Year-Over-Year Revenue Growth in Second Quarter 2026Verdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
0

No SEC Form 4 filings for $NICE in the last 30 days.

See all $NICE insider activity →

Yorkville Ives initiates NICE Systems stock coverage citing AI opportunity

Yorkville Ives initiated coverage on NICE Systems (NASDAQ:NICE) with an In Line rating and $125 price target. The company's AI and cloud opportunities are noted, but competition is a concern. NICE reported Q2 2026 earnings of $2.70 per share and $782.3M revenue, beating estimates. Cloud revenue rose 12.6% YoY, and AI revenue increased 52% YoY. Oppenheimer and RBC Capital also issued positive ratings and price targets.

NICE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NICE (NICE Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent NICE coverage spans financial news, technology and mergers & acquisitions.

What's driving NICE

AlphAI scores every news story that mentions NICE with an AI model for sentiment and relevance, and aggregates insider trades from NICE Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NICE

Score

Yorkville Ives initiates NICE Systems stock coverage citing AI opportunity

Yorkville Ives initiated coverage on NICE Systems (NASDAQ:NICE) with an In Line rating and $125 price target. The company's AI and cloud opportunities are noted, but competition is a concern. NICE reported Q2 2026 earnings of $2.70 per share and $782.3M revenue, beating estimates. Cloud revenue rose 12.6% YoY, and AI revenue increased 52% YoY. Oppenheimer and RBC Capital also issued positive ratings and price targets.

$AAPLMed

Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

$GOLow

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Notable upgrades include Target (TGT) to Buy at HSBC with a $190 target, and Grocery Outlet (GO) to Buy at Bank of America with a $15 target. Downgrades include Ally Financial (ALLY) to Equal Weight at Wells Fargo with a $42 target, and Moderna (MRNA) to Sell at Citigroup with an $80 target.

$NICEMed

Wed: Nice bucks market

Tel Aviv Stock Exchange indices fell, with Tel Aviv 35 down 0.26% and BlueTech Global down 0.12%. Nice gained 1.68% on acquisition rumors, while Camtek dropped 2.73%. Banking and retail sectors saw declines. Turnover was NIS 3.84B in equities and NIS 6.63B in bonds.

$NICEHighAI 9/10

Brookfield in talks to buy Nice’s Actimize for $2b - report

Brookfield is in talks to acquire Actimize from NICE for $2 billion, though the deal is not finalized. NICE, with a $6.9 billion market cap, has seen low single-digit stock gains this year. Brookfield manages over $1 trillion in assets and has a $73.5 billion market cap. NICE reported Q2 2026 revenue of $782 million, with $83.2 million in net profit.

$NICEMed

NICE Soars As AI Pivot And Upgrade Spark Rally

NICE Ltd. (NICE) shares rose after an analyst upgraded the stock to Buy and the company announced plans to sell its Actimize unit for $2B to focus on AI and cloud platforms. The rally follows a strong Q2 earnings beat and new customer wins. The company has strong margins and cash generation but faces challenges in revenue conversion and profit pressure.

Related tickers